Schering-Plough Cutbacks Underscore Consumer Business Importance
This article was originally published in The Tan Sheet
Executive Summary
Schering-Plough will look to the diversity of its business with strong OTC and animal health divisions to help weather a major company restructuring that will cut roughly 5,500 jobs and achieve $1.5 billion in cost savings by 2012
You may also be interested in...
Sea Changes In Regulation And The Market: Top Stories Of 2008
When an iconic drug brand drew scrutiny on Capitol Hill for possibly violating FDA's policy against combinations of drugs and dietary supplements, OTC and supplement interests took notice
Claritin Sales Grow For Schering-Plough Despite Zyrtec OTC Competition
OTC Claritin sales advanced almost 10 percent in Schering-Plough's fiscal 2008 first quarter despite the "aggressive launch" of Johnson & Johnson's OTC Zyrtec, S-P says
ENHANCE Results Do Little To Enhance Merck’s Statin Product Outlook
The Merck/Schering-Plough combination cholesterol therapy Vytorin has failed to demonstrate significant benefit over simvastatin alone in preventing formation of arterial plaque in the ENHANCE trial